Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion

FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo

(Reuters) -Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.

Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close.

Point Biopharma’s shares soared 84% in premarket trading.

The companies expect the deal to close by the end of 2023.

Source: Read Full Article

Related posts:
  1. You don’t have to go cold turkey on red meat to see health benefits
  2. Assessing state of the art in AI for brain disease treatment
  3. Mastercard, b.well launch tech to enable patient ID verification
  4. What Is The TikTok Milk Crate Challenge? Experts Say This Viral Trend Could Cause Serious Injuries
  5. Biomaterial-delivered one-two punch boosts cancer immunotherapy